Tech Company M&A Transactions
RetroSense Therapeutics Acquisition
On 9/6/2016, RetroSense Therapeutics was acquired by Allergan Plc. Allergan Plc disclosed that the acquisition price was $60 million.
Transaction Overview
Company Name
Acquired By
Announced On
9/6/2016
Transaction Type
M&A
Amount
$60,000,000
M&A Terms
Under the terms of the transaction, Allergan has paid RetroSense a $60 million upfront payment, and has agreed to potential regulatory and commercialization milestone payments related to its lead development program, RST-001, a novel gene therapy for the potential treatment of Retinitis Pigmentosa (RP).
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
330 East Liberty Street LL
Ann Arbor, MI 48104
USA
Ann Arbor, MI 48104
USA
Phone
Website
Email Address
Overview
Led by a team of seasoned veterans, RetroSense Therapeutics was founded in 2009 to develop a novel gene therapy approach to vision restoration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sean Ainsworth
Chief Medical Officer
Peter Francis
Chief Operating Officer
Thomas Rea
Browse more venture capital transactions:
Prev: 9/6/2016: TernPro venture capital transaction
Next: 9/6/2016: Advanced Cooling Therapy venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. All VC database entries reported here are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs